|Last Price$6.35||Day Change (%)0.00%|
|Open Price$6.30||Day Change ($)0.00|
|Day Range6.26–6.48||52-Week Range3.05–8.61|
As of Mon 7/6/2015 5:00:00 PM | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.